Holen Sie sich die Stockscreener-App
0.7901
1.24%
-0.0099
Schlusskurs vom Vortag:
$0.80
Offen:
$0.8
24-Stunden-Volumen:
474.29K
Relative Volume:
0.05
Marktkapitalisierung:
$32.92M
Einnahmen:
$500.00K
Nettoeinkommen (Verlust:
$-19.45M
KGV:
-0.418
EPS:
-1.89
Netto-Cashflow:
$-18.22M
1W Leistung:
-1.06%
1M Leistung:
-58.63%
6M Leistung:
-22.54%
1J Leistung:
-34.97%
1-Tages-Spanne:
$0.7713
$0.8199
1-Wochen-Bereich:
$0.6981
$0.858
52-Wochen-Spanne:
$0.37
$3.65
Imunon Inc Stock (IMNN) Company Profile
Firmenname
Imunon Inc
Sektor
Branche
Telefon
(609) 896-9100
Adresse
997 LENOX DRIVE, LAWRENCEVILLE
Vergleichen Sie IMNN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMNN
Imunon Inc
|
0.7901 | 32.92M | 500.00K | -19.45M | -18.22M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Imunon Inc Aktie (IMNN) Neueste Nachrichten
IMNN Presents Promising Phase 2 OVATION 2 Study Results at ESMO Congress | IMNN Stock News - GuruFocus
IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 - GuruFocus
IMUNON reports promising ovarian cancer therapy data at ESMO - Investing.com
IMUNON Presents Positive Phase 2 Translational Data of - GlobeNewswire
Breakthrough in Ovarian Cancer Treatment: New Drug Amplifies Immune Response by 62-fold, Phase 3 Trial Begins - Stock Titan
IMUNON reports durability data for COVID-19 vaccine alternative By Investing.com - Investing.com India
IMUNON reports durability data for COVID-19 vaccine alternative - Investing.com Australia
IMNN Showcases Positive Phase 1 Results for DNA Plasmid Vaccine - GuruFocus
IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™ - The Manila Times
IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™ | IMNN Stock News - GuruFocus
IMUNON Reports Six-Month Durability and Manufacturing Benefits of PlaCCine® DNA Vaccine Technology Over mRNA Vaccines, Seeks Strategic Partnership - Nasdaq
IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract - GlobeNewswire
IMUNON at ASCO 2025: Changing the micro-tumour environment in advanced ovarian cancer - pharmaphorum
Imunon Inc. appoints new CFO following termination - Investing.com Australia
Imunon Inc. appoints new CFO following termination By Investing.com - Investing.com South Africa
Imunon Appoints Kimberly Graper as Interim CFO - TipRanks
ImunonTerminates CFO David Gaiero's Service Agreement - MarketScreener
Why Imunon, Inc. (IMNN) Surged Last Week - MSN
Imunon regains Nasdaq compliance with bid price By Investing.com - Investing.com South Africa
Imunon Regains Nasdaq Compliance with Bid Price - TipRanks
Imunon regains Nasdaq compliance with bid price - Investing.com
Imunon (NASDAQ:IMNN) Raised to Sell at Wall Street Zen - Defense World
Top Companies in the NASDAQ by Kalkine Leading Market Performers Today - Kalkine Media
Equities Analysts Offer Predictions for Imunon Q2 Earnings - Defense World
IMUNON to Present at the Zacks SCR Life Sciences Virtual Investor Forum on June 12th - GlobeNewswire
Phase 3 DNA Immunotherapy Developer IMUNON Opens Live Q&A with Investors Next Week - Stock Titan
ASCO25: Imunon shares positive results from trial of IMNN-001 for ovarian cancer - Yahoo Finance
IMUNON Announces Data Presented at ASCO Reinforces - GlobeNewswire
Imunon announces data from Phase 2 OVATION 2 study on IMNN-001 - TipRanks
IMUNON Announces Data Presented at ASCO Reinforces Unprecedented - GuruFocus
IMNN: Promising Phase 2 Results in Ovarian Cancer Treatment | IMNN Stock News - GuruFocus
IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study - Yahoo Finance
Imunon CEO says company ‘has never been stronger’ - TipRanks
IMNN Advances Cancer Treatment with Promising Phase 2 Results | IMNN Stock News - GuruFocus
IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDA - GuruFocus
IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS | IMNN Stock News - GuruFocus
IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS - The Manila Times
Breakthrough Ovarian Cancer Drug Extends Patient Survival by 13 Months in Phase 2 Trial, ASCO Data Shows - Stock Titan
Should You Buy, Sell, or Hold Shopify Stock in June 2025? - The Globe and Mail
IMUNON launches up to $9.75M securities offering - MSN
Imunon Inc. Faces Nasdaq Delisting Over Compliance Issues By Investing.com - Investing.com Canada
Imunon (IMNN) Announces Plans to Offer 22.03 Million Shares | IM - GuruFocus
Imunon Faces Nasdaq Delisting Due to Non-Compliance - TipRanks
Imunon Inc. Faces Nasdaq Delisting Over Compliance Issues - Investing.com
Public market insider selling at TerraVest Industries (TVK) - The Globe and Mail
Imunon, Inc. (IMNN) Raises $3.25M in Private Placement, Eyes $6.5M More - Yahoo Finance
Finanzdaten der Imunon Inc-Aktie (IMNN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Imunon Inc-Aktie (IMNN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lindborg Stacy | President and CEO |
Aug 15 '24 |
Buy |
0.98 |
25,000 |
24,500 |
264,166 |
| Tardugno Michael H | Executive Chairman of Board |
Aug 15 '24 |
Buy |
1.03 |
25,000 |
25,750 |
353,346 |
0.68%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):